Amryt Pharma Share Discussion Threads

[tiananmen] 05/12/2019 14:58

As there is no sign of Phase III coming anytime soon for Amryt, my patience has run short. However, Futura Medical are due their Phase III results on MED 2005 in the next week or two. Their results are expected to be successful and currently trading at an attractive share price of 30p.This is expected to jump to 62p at a conservative estimate and Liberum has suggested it could reach £1.29 upon successful results.Worth considering as we wait for Amryt to gather momentum.https://www.proactiveinvestors.co.uk/companies/news/908286/futura-medical-worth-double-current-value-suggests-research-house-908286.html

[papillon] 05/12/2019 12:57

I did have 5,250, chica and tiananmen, but am now down to 4,000 having sold 250 weeks ago and another 1,000 (2 x 500) on Monday. I'll hang on to them as I'm still in profit having bought most of them at the equivalent of around 80p early this year.

Where's the share price going for what remains of 2019? No idea as I can't predict share prices, or what, if any, news AMYT might come out with in the short term. A continuing gradual fall wouldn't surprise me until we get closer to the AP101 phase III results in 2020, but wtfdik?

[tiananmen] 05/12/2019 11:13

Have sold out myself, too many delays and no news, I will buy back in at a later stage and at an attractive price again

[chica1] 05/12/2019 11:07

I have to admit I have sold out yesterday.I bought shares here only for the AP103 Gene Therapy but I dont think we will see anything until 2025 at the earliest.
They seem to be pumping 10's of million of Euro's into AP101 which I think is no better than an off the counter €6 bottle.
(and I have done a comparison test myself,not scientific I know)

[papillon] 01/12/2019 21:53

"still only at .18 pence in old money so original investors are still down 25% even though the company has been 'transformed'"

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Just goes to show how overpriced AMYT were when they listed in May 2016, Bronxville. I'm baffled by the absence of the funds managed by Neil Woodford from the list of big percentage shareholders taking part in the initial 24p placing! LOL. After all Neil Woodford had a penchant for investing in biotech's that lost his funds money!

I hate to admit this, but mdalos got his timing spot on when selling AMYT when he did.

[papillon] 01/12/2019 21:40

Bronxville
Posts: 1,325
Price: 112.00
No Opinion
RE: Papillion..no Nasdaq listing
Today 17:20
Yep Pap and still only at .18 pence in old money so original investors are still down 25% even though the company has been 'transformed'...
++++
I'm still trying to figure why AP103 has fallen so far behind KB103..
Then again AP101 is a very tardy as well...

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

I'm gutted by the news that they currently have no plans to list on Nasdaq, Bronxville. Mug that I am I believed that they would fulfil their promise to list on Nasdaq within 90 days of the Aegerion deal being finalised. It's the only reason I'm still invested. Fortunately I'm still in profit, but for how long? I should have known better because Amryt have form when it comes to over promising.

[papillon] 01/12/2019 15:46

Bronxville
Posts: 1,325
Price: 112.00
No Opinion
Papillion..no Nasdaq listing
Today 12:30
because there are still to many uncertainties...

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Well in that case, Bronxville, the company shouldn't make promises it's unable to fulfil!

[papillon] 30/11/2019 21:26

We were promised a Nasdaq listing within 90 days of the completion of the Aegerion deal. Amryt? Yet another AIM company that doesn't fulfil it's promises! I'm disappointed, but can't say I'm surprised. It is AIM after all!

Cathal Friel went even further and stated that he expected the Nasdaq listing in October! I thought he meant October 2019! Silly me! He obviously meant October 2020, or maybe 2021, or 2022, or 2023, or ….! Friel needs to purchase a new crystal ball because his prediction has turned out to be rubbish!

[papillon] 30/11/2019 21:14

mdalos1 - 28 Nov 2019 - 10:14:35 - 5148 of 5158
Amryt Pharma - AMYT
Just realised I'd have lost 20% of my Loot by now if I hadn't sold when I did.

The CVRs are obviously worthless... but you never know.... some free money one day in the dim & distance future perhaps ?

Did anybody work out just how many new shares would most likely be issued in order for a realistic US Nasdaq listing to take place and just how dilutive that exercise would be to existing AIM shareholders ?.. be careful what you wish for !!!

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

"The CVR;s are obviously worthless" You could be right. We'll find out soon enough next year!

[chica1] 30/11/2019 15:22

I'm pretty sure diamondstar said early 2019 that AP103 was only 6 months behind KB103.

[bermudashorts] 30/11/2019 13:29

I assume you're referring to KB103, Krystal's gene therapy for EB. They announced the KB103 clinical trial results back in June so I'm not sure how AP103 could ever have been just 6 months behind.

Krystal's gene therapy uses a viral vector - the herpes simplex virus. The whole point about AP103 and what differentiates it from other gene therapies is the fact that it uses a synthetic polymer vector rather than a viral vector and so although Krystal's progress is interesting, surely it's no more relevant than any other gene therapy or indeed any other drug in development for EB?

[chica1] 30/11/2019 12:33

Well that's better but I was under the impression that we were only 6 months to a year behind Krystal Biotech.
It looks more like 3 years or more now.

[bermudashorts] 30/11/2019 11:05

chica- It says 'clinical proof of concept expected by 2023' - the operative word being 'clinical'.

In other words results of a phase I/IIa proof of concept trial by 2023.


gnmartin - thanks for the link, appreciated.

[chica1] 30/11/2019 09:52

I notice from the media leaflet that gnnmartin posted that AP103 will only file Proof of Concept finding in 2023.
Why so long?
I thought AP103 was entering clinical trials in 2019.

[chica1] 28/11/2019 14:18

gnnmartin

Did anyone ask about the Nasdaq?
Was AP103 mentioned?

Thanks

[gnnmartin] 28/11/2019 13:12

I thought (or perhaps it was a guess) that the US listing was primarily aimed at letting the creditors who had got Amryt shares in the Aegerion purchase sell those shares, since (if I understood correctly) the creditors are primarily in the business of lending rather than investment in companies.

Anyhow, Amryt said in answer to other questions las night that they were fully funded to complete the AP101 trial, and they expected to be EBITDA positive by the end of 2020.

[bazworth] 28/11/2019 00:40

Thank you for posting the update!

Reckon we will do ok!

[gnnmartin] 28/11/2019 00:03

I've just listened to Amryt present at the Shares do near Tower Bridge. No mention of a US listing. The story sounds good without it, but those hoping for a big surge in the share price following a US listing will be disappointed.

[papillon] 26/11/2019 23:18

radar
Posts: 3,004
Price: 115.00
No Opinion
Looks like
Today 12:48
There’s trouble in the camp and the originators could be going it alone.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

PMSL. ROFLMAO. radar is as thick as 2 short planks. How can they "be going it alone"? There's the small matter of the 8.4m Euro's grant from the Irish Govt to develop AP103. The 3 partners, AMYT, UCD & Curran have to match that funding. AMYT are the lead partner. Where would the Branca Bunis team find 8.4m Euro's on their own? radar? PILLOCK.

[papillon] 25/11/2019 19:55

Cionnathagad
Posts: 71
Price: 115.50
No Opinion
RE: Branca Bunús..No mention of Lara Cutlar
Today 14:42
Oh yeah it's the same deal.I just find it strange Amryt is not mentioned.
Bronxville is right Lara Cutlar (who now works at Amryt)was one of the original scientists working on this technology since 2012 and she's not mentioned.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Why should Amryt be mentioned? Why do you find it strange, Cionnathagad? Branca Bunis is a company formed to hold the interest of UCD and it team of scientists in AP103. This company has nothing to do with Amryt.

Why should Lara Cutlar be mentioned in connection with Branca Bunis? Why would you expect her to be mentioned, Cionnathagad? She's no longer part of the UCD team since she is currently employed by Amryt. It's the same for anybody who leaves their previous employment and goes to work for another employer. As far as your previous employer is concerned you become a "non" person when you go to work for someone else. The fact that UCD (Branca Bunis) and Amryt are partners in developing AP103 makes no difference. Branca Bunis and Amryt are separate company's. For instance major oil companies (for example Shell and Total) spread their risk by partnering on the development and production of a large oil discovery. However even though they may be partners on a certain project that doesn't mean that Shell would still mention a senior employee/director if they went to work for Total. That wouldn't make commercial sense.

[papillon] 25/11/2019 12:52

Well the UCD are stated as partners in the AP103 project, chica. It just looks like the new company is a UCD spin off and that will hold it's (and the teams) interest in AP103. They'll have to raise money to match the Irish government grant so perhaps this move makes it easier to raise their share of the costs?

Again my main gripe at the moment is not with any delay in progressing AP101, or AP103, but the delay in announcing a date for the Nasdaq listing. Only then we will see a significant rerate in the AMYT sp, IMO, in the short term.